# BIOS health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bios-health

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, UK
- Website: www.bios.health
- Total disclosed funding: $4.5M
- Latest round: Seed (Dec 4, 2018)
- Investors on record: 7

## About

BIOS Health Inc. focuses on developing advanced neural interfaces and AI solutions to enhance understanding and treatment of the nervous system, aiming for improved patient outcomes in healthcare.Founded in 2015 in Cambridge, UK, BIOS Health Inc. specializes in neural technology, particularly in reading and writing neural data. The company was co-founded by Emil Hewage and Oliver Armitage. BIOS Health has successfully completed 4 funding deals since inception, with the latest round of funding occurring on June 18, 2023, raising USD 20.00 mn from investors including Selvedge Venture, XTX Ventures, and others. Emil Hewage serves as the CEO.BIOS Health specializes in developing advanced neural interfaces and artificial intelligence solutions designed to read and write neural data, facilitating real-time insights into the nervous system’s functionality. Its core offerings encompass a proprietary neural interface and AI platform that enable the creation of neural digital therapies, which leverage real-time feedback from the nervous system to enhance the precision of pharmaceutical treatments. This innovative technology aims to address a multitude of conditions, particularly those linked to cardiovascular diseases, by providing personalized neural therapies that improve patient outcomes. The company targets healthcare providers, research institutions, and pharmaceutical companies across various geographical markets, including North America and Europe, significantly broadening the potential client base and end-users for their groundbreaking solutions.The revenue structure of BIOS Health is driven by partnerships and collaborations that focus on the co-development of neural digital therapies. The company engages in long-term partnerships with pharmaceutical companies and healthcare organizations, facilitating access to their Neural Dosing Platform, which personalizes neural therapies. These transactions are structured around collaborative agreements, where partners benefit from tailored solutions informed by high-quality neural recordings and AI capabilities. While specific pricing plans for individual products or services are not disclosed, the company’s innovative approach suggests a value-based pricing model that aligns with the effectiveness of its therapies and the insights provided by its technology. As a result, BIOS Health's revenue generation strategy emphasizes building strategic alliances to drive the adoption of its advanced neural solutions in the healthcare market.In June 2023, BIOS Health Inc. raised USD 20.00 mn in venture funding, which will be allocated towards expanding market share and revenue growth. The company is focused on launching new products designed to enhance its neural therapies and plans to expand into new markets in North America and Europe by the end of 2024. This funding round was co-led by Selvedge Venture and XTX Ventures, alongside participation from other investors, supporting BIOS Health's strategic initiatives to increase its reach and effectiveness in healthcare.

## Funding rounds

- Seed, Dec 4, 2018, $4.5M — Real Ventures, AME Cloud Ventures, K5 Ventures, Endure Capital, Heuristic Capital Partners
- Seed, Mar 20, 2017 — Y Combinator, Endure Capital, Investo Max

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Endure Capital (https://capitalatlas.ai/funds/endure-capital) — Seed
- Investo Max — Seed
- Real Ventures — Seed
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Seed
- K5 Ventures (https://capitalatlas.ai/funds/k5-ventures) — Seed
- Heuristic Capital Partners (https://capitalatlas.ai/funds/heuristic-capital-partners) — Seed